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Abstract
Background: The use of combination antiretroviral therapy (cART) has become a standard of care for the
treatment of HIV infection. However, cost and resistance to cART are major obstacles for access to treatment
especially in resource-limited settings. In this study, we aimed to determine the incidence and risk factors of
treatment failure in a cohort of treatment-naïve Thai HIV-infected patients.
Methods: A retrospective cohort study was conducted among HIV-infected patients initiating their first cART at
Chiang Mai University Hospital, Thailand.
Results: From January 2002 to December 2008, 788 patients were enrolled; 365 were male (46.3%), and the mean
age was 37.9 ± 8.6 years. The median baseline CD4 count was 57.7 cells/mm
3 (IQR 22, 127). GPO-VIR
® (a fixed-dose
combination of lamivudine, stavudine, and nevirapine) was the most common prescribed cART (657 patients,
83.4%). Seventy-six patients developed virological failure given the cumulative incidence of 9.6%. The incidence of
virological failure was 2.79 (95% CI 2.47, 3.14) cases per 100 person years. Poor adherence was the strongest
predictor for virological failure. Of 535 immunologically evaluable patients, 179 (33.5%) patients developed
immunological failure. A low CD4 cell count at baseline (< 100 cells/mm
3) and the increment of CD4 cell count of
< 50 cell/mm
3 after 6 months of cART were the predictors for immunological failure (p < 0.001).
Conclusions: This study demonstrated that even in resource-limited settings, the high rate of success could be
expected in the cohort with good and sustainable drug adherence. Poor adherence, older age, and low baseline
CD4 cell count are the predictors for unfavorable outcome of cART.
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Introduction
By the year 2010, the Joint United Nations Program on
HIV/AIDS (UNAIDS) estimate that there are 1,138,020
people living with HIV/AIDS in Thailand [1]. The
mathematic model describing the epidemic trends using
the Asia Epidemic Model software projected that there
will be 10,835 new HIV cases each year [1]. In Thailand,
it was only after the establishment of the National
Access to Antiretroviral Program for People living with
HIV/AIDS (NAPHA) in 2002 that combination antire-
troviral therapy (cART) became widely available free of
charge throughout the country [2]. In a previous study
from Thailand, treatment with GPO-VIR
® (a locally-
produced generic fixed-dose combination of stavudine,
lamivudine, and nevirapine) resulted in 62.7% and 93.3%
of 90 HIV treatment-naïve patients achieving undetect-
able HIV viral load at 24 and 48 weeks, respectively [3].
Despite the significant reduction in morbidity and mor-
tality among HIV-infected patients receiving cART, a
considerable number of patients fail to achieve a sus-
tained virological and immunological response to ther-
apy [4-7]. The incidence and predictors of treatment
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however, these results may not be applicable to more
heterogeneous cohorts such as in Thailand, where non-
nucleoside reverse transcriptase inhibitor (NNRTI)-
based regimen is the first line of treatment, the majority
of HIV-1 virus is subtype E (CRF01_AE), and cART is
usually initiated at a very low CD4 count. The data
regarding treatment failure from Thailand are still lim-
ited. Furthermore, the number of long-term cART treat-
ment cohorts is scarce. Hence, our primary objective
was to study the incidence and risk factors for treatment
failure in a large cohort in northern Thailand. Such data
would assist physicians in Thailand as well as in similar
resource limited settings predicting and detecting treat-
ment failure earlier in the course of cART.
Materials and methods
Study design and population
A retrospective cohort study was conducted at Chiang
Mai University Hospital, an 1800-bed, tertiary-care hos-
pital in Northern Thailand. All patients with documen-
ted HIV infection who were under medical care at the
HIV Clinic and met the following criteria were included:
1) ≥ 15 years of age, 2) naïve to cART, 3) initiated their
first cART regimen between January 1, 2002 and
December 31, 2008, and 4) had at least 2 consecutive
visits after cART initiation.
Data collection
Baseline demographic data at the time of cART initia-
tion were recorded including sex, age at cART initiation,
race (Thai or hill-tribe), residential area (urban or rural
area), type of health insurance (government fund, social
security fund, Global Fund for AIDS, TB, and malaria,
no funding support), and route of HIV transmission
(men who have sex with men (MSM), heterosexual,
injection drug user (IDU)). Medical data included diag-
nosis of AIDS-defining illness prior to cART initiation,
cART regimen, date when cART was started, body
weight, and self-reported adherence to cART was evalu-
ated by asking patients the number of missing doses of
antiretroviral drugs between visits. Baseline laboratory
data included CD4 cell count, hemoglobin level, hepati-
tis B surface antigen (HBs Ag), anti-hepatitis C virus
antibody (anti-HCV) and plasma HIV-1 RNA level (if
available). Patients were followed up every 2-4 weeks
during the first few months of cART initiation, and
every 3-6 months thereafter. CBC and CD4 cell counts
were measured every 6 months whereas plasma HIV-1
RNA quantification was done every 6 to 12 months.
Definitions
cART was defined as a treatment regimen containing a
non-nucleoside reverse transcriptase inhibitor (NNRTI)
(either nevirapine or efaviren z ) ,o rap r o t e a s ei n h i b i t o r
(PI) plus 2 nucleoside reverse transcriptase inhibitors
(NRTIs), or triple NRTIs (zidovudine/lamivudine/
abacavir).
Adherence rate (%) was defined as (total doses taken/
total doses prescribed) × 100, and was classified as
100%, 95-99%, 90-94%, 80-90%, and < 80% categories.
Due to missing data on adherence rate at the beginning
of our cohort, it was available in the majority of patients
only in the last 4 years of follow-up.
Treatment failure was defined as either virological fail-
ure or immunological failure. Virological failure was
defined as 1) incomplete virological response, i.e., con-
firmed HIV-1 RNA > 50 copies/ml after 48 weeks of
cART, or 2) virological rebound, i.e., confirmed HIV-1
RNA > 50 copies/ml after initial virological suppression.
Immunological failure was defined as failure to achieve
CD4 cell count > 350 cells/mm
3 despite virological sup-
pression (HIV-1 RNA < 50 copies/ml) after ≥ 2y e a r so f
cART.
Statistical analysis
The cumulative incidence of treatment failure was cal-
culated by the number of patients who had treatment
failure over the number of patients who received cART
during the study period. The incidence rate of virologi-
cal failure was calculated by the number of patients who
developed virological failure over the person-time from
cART initiation to the development of virological failure.
Patients who did not develop virological failure were
censored as of December 31, 2008.
Baseline characteristics between groups of patients
with and without treatment failure were compared using
Student’s t test for normally distributed continuous data,
or Mann-Whitney U tests for non-normally distributed
continuous data. Chi-square or Fisher exact tests were
used to compare categorical data as appropriate.
Logistic regression models were used to identify cov-
ariates that were associated with treatment failure. Fac-
tors that were significant at the p-value < 0.10 in the
univariate analysis were then evaluated in multivariable
model using forward stepwise procedures.
All analyses were performed using Stata statistical
software: Release 10.0 Stata Corporation, College station,
TX, 2007). All p-values were two-sided. A level of signif-
icance of 0.05 was used to guide interpretation of rela-
tionships in final multivariable model.
The study was approved by the Faculty of Medicine,
Chiang Mai University Ethical Committee.
Results
Patient Characteristics
During the study period from January 2002 to December
2008, 812 treatment-naive HIV-infected patients were
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Chiang Mai University Hospital. 24 patients (3%) were
excluded from the analysis; 6 of these died shortly after
cART initiation from lymphoma (2 patients), Pneumocystis
pneumonia (1) and unknown causes (3). 18 patients were
lost to follow-up after a median time of 18 weeks after
cART initiation. The remaining 788 patients (97.0%) were
followed up regularly for at least one year and fulfilled the
inclusion criteria for the analysis of virological failure.
Among 606 patients who were followed up for at least 2
years, 71 patients developed virological failure; therefore,
there were 535 patients included in the analysis of immu-
nological failure (Figure 1). Table 1 shows the baseline
characteristics of the 788 patients in this cohort. NNRTI-
based regimen was initiated in 774 patients (98.2%) and
GPO-VIR
® was the most commonly prescribed first line
regimen (84.1%).
Outcome of cART
During the study period of 6 years and a median follow-up
duration of 3.63 years (IQR 1.66, 5.19), 76 of 788 patients
developed virological failure giving the cumulative inci-
dence of 9.6% by on-treatment analysis. The cumulative
incidence of virological failure was 12.3% (100 of 812
patients) by intention-to-treat analysis. The incidence rate
of virological failure was 2.79 cases (95% CI 2.47, 3.14) per
100 person-years. In 712 patients who had no virological
failure, the median CD4 cell count increased from the
baseline of 60 (IQR 24, 130) cells/mm
3 to 222 (IQR 150,
310) cells/mm
3 in 12 month (p < 0.001). In 76 patients
with virological failure, the median CD4cell count
increased from the baseline of 42 (IQR 20, 100) cells/mm
3
to 187 (IQR 120, 210) cells/mm
3 (p < 0.001).
Among 535 patients who were able to follow up for at
least 2 years and included in the analysis of immunolo-
gical failure, 179 patients (33.5%) experienced immuno-
logical failure despite virological suppression. After 2
years of cART initiation, the increment of median CD4
cell count from baseline was 152 (IQR 105, 214) cells/
mm
3 and 294 (IQR 209, 370) cells/mm
3 among those
with and without immunological failure, respectively (p
< 0.001). The proportion of patients achieving CD4 cell
count of ≥ 350 cell/mm
3 after 2 years of cART was 200/
339 patient (59.0%) and 154/193 patients (79.8%) among
those initiated cART at CD4 cell count of < 100 cell/
mm
3 and ≥ 100 cells/mm
3, respectively (p < 0.001).
Risk factors for virological failure
Besides age at the cART initiation (36.6 ± 7.9 years
among those with virological failure and 39.3 ± 8.6 years
18 patients were lost to follow-up
6 patients died after cART was started, but before the schedule
visit
• 2 died from lymphoma
• 1 died from Pneumocystis pneumonia
• 3 died from unknown cause (unavailable data)
812 patients started cART between January 2002 and December 2008
788 patients were included for baseline characteristics and virological analysis
535 patients were included for immunological analysis
182 patients were followed < 2 years
71 patients developed virological failure 
Figure 1 Diagram of HIV-infected patients enrolled at HIV Clinic of Chiang Mai University Hospital from January 2002-December 2008.
Khienprasit et al. AIDS Research and Therapy 2011, 8:42
http://www.aidsrestherapy.com/content/8/1/42
Page 3 of 7among those without virological failure, p = 0.011),
there was no difference in baseline characteristics
between 2 groups including sex, race, route of HIV
transmission, residential area, type of health insurance,
OIs before cART, cART regimen, and body weight. In
addition, baseline laboratory data were not different
between groups including CD4 cell count at cART
initiation.
The univariate and multivariate analyses to determine
the predicting factors for virological failure were shown
in Table 2. In multivariate analysis, factors associated
with virological failure were adherence of < 95% [OR
86.49 (31.19-239.80), p < 0.001] and age < 40 years [OR
2.28 (1.22-4.25), p = 0.04].
Risk factors for immunological failure
Among those with and without immunological failure,
92 of 179 (51.4%) vs. 138 of 356 (38.8%) were male (p =
0.005) and 111 of 179 (62.0%) vs. 186 of 356 (52.3%)
had OIs before initiation of cART (p = 0.032). There
was no difference in other baseline characteristics
between 2 groups including age, race, route of HIV
transmission, residential area, type of health insurance,
cART regimen, and body weight. Baseline laboratory
data were also not different between groups, except for
CD4 cell count at cART initiation and HCV serology.
Among those with and without immunological failure,
the median CD4 cell count was 44 (IQR 20, 87) cells/
mm
3 vs. 78 (33, 150) cells/mm
3 (p < 0.001) and 23/138
(16.7%) vs. 28/283 (9.9%) had positive HCV antibody (p
= 0.046).
Table 3 shows the univariate and multivariate analyses
to determine the predicting factors for immunological
failure. In univariate analysis, factors associated with
immunological failure were male, history of OIs prior to
cART initiation, lower baseline CD4 cell counts, and
lower CD4 cell increase after 6 months of cART. The
baseline CD4 cell count of < 100 cells/mm
3 [OR 2.69
(1.73-4.18), p < 0.001], and CD4 cell increase of < 50
cell/mm
3 after 6 months of cART [OR 2.39 (1.54-3.73),
p < 0.001], remained significant in the multivariate
analysis.
Discussion
This is a large cohort of HIV-infected patients with mid-
dle or low socioeconomic status from a tertiary care
hospital in northern part of Thailand. During the study
period of 6 years and a median follow-up duration of
3.63 years (IQR1.66, 5.19), the cumulative incidence of
treatment failure was 12.3% and 9.6% by intention-to-
treat and on treatment analyses, respectively. This result
is similar to failure rates found in a previous study by
Anekthanonon et al from Bangkok, Thailand (2.4% by
on treatment and 19.8% by intention- to -treat analysis)
[11] and in the same range of 3-27% from many cohorts
[10,12,13]. The wide range of virological failure from
many cohorts could be attributable to differences in
definition of treatment and virological failure between
studies as well as the length of follow-up. However, in
this study in which majority of patients were infected
with HIV-1 subtype CRF01_AE, the immunological and
virological outcomes are comparable to those from
many US and European cohorts in which majority of
patients were infected with HIV-1 subtype B, and those
from African cohorts in which majority of patients were
infected with HIV-1 subtype C [10,14-16]. The inci-
dence rate of virological failure in our study was 2.79
cases per 100 person-years which is relatively low
Table 1 Baseline characteristics of 788 HIV-infected
patients enrolled at HIV Clinic of Chiang Mai University
Hospital from January 2002 to December 2008
Characteristics Values
Male 365 (46.3)
Age (years) 39 ± 8.6
Route of transmission (N = 775)
Heterosexual 740 (95.5)
Homosexual 27 (3.5)
IVDU 5 (0.6)
Unknown 3 (0.4)
Race (Thai) 764 (97.0)
Baseline body weight (kilograms) (N = 628) 54.4 ± 10.4
Residential area (Urban area) 597 (82.3)
Health insurance (N = 777)
No 46 (5.9)
Government fund 142 (18.3)
Social security fund 418 (53.8)
Global Fund for AIDS, TB, Malaria 171 (22.0)
Combination antiretroviral therapy (cART)
Nevirapine-based 657 (83.4)
Efavirenz-based 117 (14.8)
Protease inhibitor-based 8 (1.0)
Zidovudine/lamivudine/abacavir 6 (0.8)
Opportunistic infections (OIs) (N = 782) 490 (62.7)
OIs before cART 434 (55.5)
Tuberculosis 198 (25.3)
Adherence ≥ 95% 754 (95.7)
Laboratory findings
Baseline CD4 cell counts (median, IQR) (cells/mm
3) 57.7 (22, 127)
Baseline CD4 cell counts < 100 cells/mm
3 525 (66.6)
Baseline CD4 cell counts 100-199 cells/mm
3 195 (24.7)
Baseline CD4 cell counts ≥ 200 cells/mm
3 68 (8.7)
Baseline Hemoglobin level (mg/dL) 11.2 ± 1.9
Positive anti-HCV antibody (N = 599) 61(10.2)
Positive HBs-antigen (N = 608) 66 (10.9)
Values are number (%) or mean ± standard deviation, unless otherwise
specified
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to 13.6 cases per 100 person-years in other cohorts
[9,17]. This high response rate may be from the very
high adherence rate in our cohort.
We found that adherence of < 95% and age < 40 years
were the independent predicting factors for virological
failure. Although adherence has been demonstrated to
be important in many clinical cohorts, [18-21]there is
discordance of results depending on types of adherence
measurement. In our study, the data on adherence were
collected according to the patient’s self report of the
amount of medication taken between visits without
standardized set of questions. Therefore, the result may
not be completely reliable. However, it is still demon-
strated to be an independent factor for treatment failure.
The finding that younger age at cART initiation was the
risk factor for virological failure is similar to other stu-
dies [14,22]. Increased age may be a marker for greater
maturity, lifestyle stability, and disease-specific educa-
tion; these factors are likely to affect long-term
adherence to therapy [14,23]. However, younger age and
poor adherence were both independent risk factors for
virological failure.
The SWISS HIV Cohort Study showed that only 39%
of individuals treated with cART reached CD4 T-lym-
phocyte count of 500 cells/mm
3 [15]. Many HIV cohorts
demonstrated factors potentially affect the recovery of
CD4 T- lymphocyte including age, HCV serology, dura-
tion of HIV-1 infection, CDC stage, baseline HIV-1
RNA levels, baseline CD4 count, and adherence of
cART [8-10,13,24]. Our study found that there was sig-
nificant lower proportion of patients achieving CD4 cell
count of ≥ 350 cell/mm
3 after 2 years of cART between
those with baseline CD4 cell count ≤ 100 cell/mm
3 and
those with higher baseline CD4 count (59.0% vs. 79.8%).
It has been hypothesized that patients who initiated
cART late in the course of disease may have thymic
damage and limitation of T cell production and prolif-
eration [25,26]. We could also demonstrate that the
increment of the CD4 cell count of < 50 cells/mm
3 after
Table 2 Comparisons of clinical parameters to determine risk factors of virological failure among 788 HIV-infected
patients
Variables Univariate analysis Multivariate analysis
Odds Ratio (95% CI) P-value Odds Ratio (95%CI) P-value
Male vs. female 0.95 (0.65-1.69) 0.847 - -
Age < 40 vs. ≥ 40 years 2.06 (1.23-3.46) 0.006 2.28 (1.22-4.25) 0.040
Heterosexual vs. non-heterosexual transmission 0.49 (0.20-1.23) 0.125
Urban vs. rural area 1.18 (0.66-2.10) 0.581 - -
No health insurance vs. had health insurance 0.77 (0.23-2.57) 0.671
OIs before cART vs. no OIs before cART 0.84 (0.53-1.36) 0.488 - -
Baseline CD4 cell count < 100 vs. ≥ 100 cells/mm
3 1.56 (0.91-2.69) 0.106 - -
Positive HCV antibody vs. negative HCV antibody 0.93 (0.35-2.44) 0.887 - -
Positive HBs Ag vs. negative HBs antigen 1.25 (0.54-2.89) 0.603 - -
Adherence < 95% vs. ≥ 95% 87.24 (32.29-235.72) < 0.0001 86.49 (31.19-239.80) < 0.001
Abbreviations: OI, opportunistic infection; cART, combination antiretroviral therapy; HCV, hepatitis C virus; HBs Ag, hepatitis B surface antigen
Table 3 Comparisons of clinical parameters to determine risk factors of immunological failure among 535 HIV-infected
patients
Variables Univariate analysis Multivariate analysis
Odds Ratio (95% CI) P-value Odds Ratio (95% CI) P-value
Male vs. female 1.67 (1.16-2.40) 0.006
Age < 40 vs. ≥ 40 years 0.92 (0.65-1.32) 0.667 - -
Heterosexual vs. non-heterosexual transmission 5.14 (0.65-40.50) 0.120 - -
Urban vs. rural area 0.86 (0.57-1.31) 0.492 - -
No health insurance vs. had health insurance 0.73 (0.23-2.33) 0.597 - -
OIs before cART vs. no OIs before cART 1.49 (1.03-2.15) 0.032 - -
Baseline CD4 cell count < 100 vs. ≥ 100 cells/mm
3 2.74 (1.81-4.15) < 0.001 2.69 (1.73-4.18) < 0.001
CD4 cell increase of < 50 vs. ≥ 50 cells/mm
3 after 6 months of cART 2.21 (1.44-3.39) < 0.001 2.39 (1.54-3.73) < 0.001
Positive HCV antibody vs. negative HCV antibody 1.823 (1.015-3.30) 0.048 - -
Positive HBs Ag vs. negative HBs Ag 1.30 (0.67-2.51) 0.434 - -
Adherence rate < 95% vs. ≥ 95% 2.87 (0.26-32.1) 0.392 - -
Abbreviations: OI, opportunistic infection; cART, combination antiretroviral therapy; HCV, hepatitis C virus; HBs Ag, hepatitis B surface antigen
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failure. Failure to achieve early CD4 recovery could be
another signal of thymic damage. Our study did not find
the difference in CD4 recovery between sexes, which
was similar to other reports [15,16,25,27]. However,
some studies reported better immunological response
among female patients [22,28]. Whether HCV co-infec-
tion adversely affects HIV treatment outcomes remains
controversial [16,29,30]. In this study, HCV seropositiv-
ity was not associated with higher risk of immunological
failure. Due to the high adherence rate among patients
evaluable for immunological failure (98.7% had adher-
ence ≥ 95%), we could not demonstrate the association
between poor adherence and immunological failure.
Our study has several limita t i o n s .F i r s t ,H I V - 1R N A
was not monitored at baseline in all patients so we
couldn’t evaluate the higher baseline HIV-1 RNA viral
load as a predictor for virological failure. Second, the
HIV-1 RNA monitoring was not regularly performed in
all patients, therefore, we could not calculate the accu-
rate time of treatment failure. It is also possible that
some patients may already have virological failure at the
time we evaluated the immunological criteria and thus
misinterpret the true CD4 cell count response. Third,
assessment and documentation of patient’s adherence to
cART was not standardized. However, this reflected the
usual clinical practice and adherence was still the stron-
gest predictor for virological failure. Fourth, this is a ret-
rospective cohort study that the accuracy of analysis
depends on the completeness of data entry into the
database. Finally, this study is limited to a single cohort,
the findings should be confirmed in other clinical
settings.
In summary, this analysis of a cohort of HIV-infected
patients under usual clinical care showed that predictors
of immunological and virological failure can be identi-
fied using data routinely recorded. The risk factors of
virological failure were poor adherence of cART and
younger age, whereas those of immunological failure
were low baseline CD4 count and slow CD4 cell recov-
ery. This study demonstrated that even in resource-lim-
ited settings, the high rate of success could be expected
in the cohort with good and sustainable drug adherence.
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